Sexually Transmitted Infections Treatment Guidelines, 2021
Open accessThe DOI matches its Crossref record; 1,459 of the 1,505 references it cites were found in a registry or an index; 371 of the 802 sources its claims cite were checked for support.
Abstract
These guidelines for the treatment of persons who have or are at risk for sexually transmitted infections (STIs) were updated by CDC after consultation with professionals knowledgeable in the field of STIs who met in Atlanta, Georgia, June 11-14, 2019. The information in this report updates the 2015 guidelines. These guidelines discuss 1) updated recommendations for treatment of Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis; 2) addition of metronidazole to the recommended treatment regimen for pelvic inflammatory disease; 3) alternative treatment options for bacterial vaginosis; 4) management of Mycoplasma genitalium; 5) human papillomavirus vaccine recommendations and counseling messages; 6) expanded risk factors for syphilis testing among pregnant women; 7) one-time testing for hepatitis C infection; 8) evaluation of men who have sex with men after sexual assault; and 9) two-step testing for serologic diagnosis of genital herpes simplex virus. Physicians and other health care providers can use these guidelines to assist in prevention and treatment of STIs.
Overview
CoChat Summary
TL;DR
These CDC guidelines update the 2015 STI treatment recommendations after expert consultation and systematic literature review, covering prevention, diagnosis, treatment, and special populations. They include updated guidance for gonorrhea, chlamydia, trichomoniasis, pelvic inflammatory disease, bacterial vaginosis, *Mycoplasma genitalium*, HPV vaccination, syphilis screening in pregnancy, hepatitis C testing, sexual assault evaluation, and HSV serology.
Key findings
- Congenital syphilis in the United States increased from 8.4 to 48.5 cases per 100,000 births during 2012–2019, a 477.4% increase.
- Three randomized controlled trials in sub-Saharan Africa found male circumcision reduced HIV acquisition among men by 50%–60%; HPTN 052 found ART for the infected partner decreased HIV transmission to uninfected heterosexual partners by 96%.
- Doxycycline postexposure prophylaxis after unprotected anal sex among MSM and transgender women reduced incident chlamydia and syphilis by 70% and 73%, respectively, but had no effect on gonorrhea.
- Expedited partner therapy trials showed reductions in chlamydia prevalence at follow-up of approximately 20% and gonorrhea of approximately 50%.
Methods
- CDC staff worked with subject matter experts to identify key questions and conduct systematic MEDLINE-based literature reviews for each section of the 2015 guidelines, focused on microbiologic eradication, symptom alleviation, prevention of sequelae, and prevention of transmission.
- Experts presented literature assessments at an in-person meeting in Atlanta, Georgia, June 11–14, 2019; evidence was rated high, medium, or low using USPSTF-style ratings, and draft recommendations underwent peer review and a public webinar before finalization.
- Recommendations for HIV, hepatitis C, cervical cancer screening, STI screening in pregnancy, HPV testing, and HAV/HBV vaccination were developed after reviewing existing published recommendations.
Limitations
- The paper states these guidelines are “a source of clinical guidance rather than prescriptive standards” and that providers should consider each person’s clinical circumstances and local disease prevalence.
- The paper states several evidence gaps, including limited data on doxycycline STI prophylaxis, no long-term data on STI postexposure prophylaxis effects on antimicrobial resistance and the microbiome, and insufficient data to recommend routine anal cancer screening with anal cytology.
- Evident from the text: many recommendations, especially for syphilis treatment, rely on decades of clinical experience and observational data rather than randomized controlled trials; the document is a broad guideline rather than a single primary study with a defined sample or comparator.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
221 Valid · 41 Not valid · 158 Not checked · 82 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Adherence can be low (48), and prevention of HIV infection, especially among women, has not been demonstrated (47,49).”
§ Sexually Transmitted Infections Treatment Guidelines, 2021 > Clinical Prevention Guidance > Primary Prevention Methods
What the sources say
- Disputedcites [47] Abdool Karim, 2010, Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women., Science sourceExperimental — accuracy not yet measured
The Results (‘HIV incidence and effectiveness’; page unavailable) report 5.6 HIV infections per 100 women-years with tenofovir gel versus 9.1 with placebo (p=0.017) in a trial of women. The Discussion states that the gel reduced HIV infection by an estimated 39%. Although the authors call for corroboration, their findings directly contradict the claim that prevention had not been demonstrated. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [49] Delany-Moretlwe, 2018, Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial., Lancet Infect Dis source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In addition, nontreponemal test titers might decrease more slowly for persons previously treated for syphilis (594,595).”
§ Sexually Transmitted Infections Treatment Guidelines, 2021 > Syphilis > Primary and Secondary Syphilis
What the sources say
- Could not verifycites [594] Ghanem, 2007, Serological response to syphilis treatment in HIV-positive and HIV-negative patients attending sexually transmitted diseases clinics., Sex Transm Infect sourceExperimental — accuracy not yet measured
The Results (page unavailable) mention a history of syphilis infection, but do not compare titre declines by prior treatment history. The paper compares response times by HIV status and syphilis stage; searches for prior treatment and serological response found no passage addressing whether previously treated patients’ titres decline more slowly. (LLM, conf=0.76)
- Disputedcites [595] Seña, 2011, Predictors of serological cure and serofast state after treatment in HIV-negative persons with early syphilis., Clin Infect Dis sourceExperimental — accuracy not yet measured
In Characteristics Associated With Serological Cure (page unavailable), the paper reports that a history of syphilis was not significantly associated with serological cure; the Discussion likewise says it found no association between history of syphilis and serological response. It mentions a prior study finding less seroreversion after repeat infection, but that is not a finding that titers decrease more slowly in previously treated persons. (LLM, conf=0.82)
Checked by a reasoning model — may be wrong.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Available data demonstrate that use of additional doses of benzathine penicillin G, amoxicillin, or other antibiotics do not enhance efficacy of this recommended regimen when used to treat primary and secondary syphilis, regardless of HIV status (591–593).”
§ Sexually Transmitted Infections Treatment Guidelines, 2021 > Syphilis > Primary and Secondary Syphilis
What the sources say
- Not checked — no full text of the sourcecites [591] Rolfs, 1997, A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection., N Engl J Med source
- Disputedcites [592] Yang, 2014, One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study., PLoS One sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) explicitly says that, among HIV-infected patients with early syphilis, one dose of benzathine penicillin G was inferior to three weekly doses for serological response at 12 months—the opposite of the claim about additional doses. The study excluded patients who received other antibiotics, so it does not establish whether adding amoxicillin or other antibiotics helps; it also does not establish the claim regardless of HIV status. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [593] Ganesan, 2015, A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis., Clin Infect Dis sourceExperimental — accuracy not yet measured
The Factors Associated With Treatment Response section reports similar responses with one versus multiple BPG doses in HIV-infected people with early syphilis. The study does not establish that adding amoxicillin or other antibiotics to the recommended regimen offers no benefit: its “other” regimens were grouped together and could be alternatives rather than additions. Nor do its findings establish the result regardless of HIV status; the Discussion also notes limited power for people with advanced immunosuppression. Page numbers were not available in our copy. (LLM, conf=0.89)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Available data demonstrate that additional doses of benzathine penicillin G, amoxicillin, or other antibiotics in early latent syphilis do not enhance efficacy, regardless of HIV status (592,593,609).”
§ Sexually Transmitted Infections Treatment Guidelines, 2021 > Syphilis > Latent Syphilis
What the sources say
- Disputedcites [592] Yang, 2014, One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study., PLoS One sourceExperimental — accuracy not yet measured
The Results report that three weekly doses of benzathine penicillin G were associated with a higher serological response than one dose in patients with HIV and early syphilis; the Discussion explicitly calls the one-dose regimen inferior at 12 months. This contradicts the claim that additional doses do not enhance efficacy. The study did not test additional amoxicillin or other antibiotics, or patients without HIV. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [593] Ganesan, 2015, A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis., Clin Infect Dis sourceExperimental — accuracy not yet measured
The Results report similar treatment responses with one versus multiple BPG doses in HIV-infected people with early syphilis. However, the Data Analysis and Definitions section says syphilis stage was not consistently captured, and the study did not establish the claim specifically for early latent syphilis, amoxicillin or other added antibiotics, or people without HIV. The Discussion further limits its conclusion to patients with preserved CD4 counts and low viral loads. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [609] Rolfs, 1997, A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection., N Engl J Med source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Available data demonstrate that additional doses of benzathine penicillin G, amoxicillin, or other antibiotics in primary and secondary syphilis among persons with HIV infection do not result in enhanced efficacy (592,593,609).”
§ Sexually Transmitted Infections Treatment Guidelines, 2021 > Syphilis > Syphilis Among Persons with HIV Infection
What the sources say
- Disputedcites [592] Yang, 2014, One dose versus three weekly doses of benzathine penicillin G for patients co-infected with HIV and early syphilis: a multicenter, prospective observational study., PLoS One sourceExperimental — accuracy not yet measured
The Results report that three weekly doses of benzathine penicillin G were independently associated with a higher serological response than one dose in HIV-infected patients with early syphilis. The Discussion says the subgroup results generally favored three doses, except among patients presenting with primary syphilis; the study did not test additional amoxicillin or other antibiotics. These findings contradict the cited sentence’s blanket claim of no enhanced efficacy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [593] Ganesan, 2015, A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis., Clin Infect Dis sourceExperimental — accuracy not yet measured
The Results (Factors Associated With Treatment Response; page not provided) found similar serologic responses with one versus multiple BPG doses in HIV-infected people with early syphilis. It also found no improved response for a pooled “other” regimen group, but the Data Analysis and Definitions section says that group combined penicillin derivatives used alone or with BPG and non-penicillin antibiotics. The paper therefore does not establish the claim specifically for additional amoxicillin or each other antibiotic. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [609] Rolfs, 1997, A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection., N Engl J Med source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
264 more claims · 126 with their cited sources checked
Create a free account to see all 502 claims and to verify the 10 references still open.
- Probably not a substantial claim. 72
- It may state two separate claims as one. 188
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and a reduction of half the risk of perinatal death (RR, 0.50; 95% CI: 0.33-0.84) (5) as long as treatment for GS been administered 30 days before delivery 5.”
From Efectividad del tratamiento de la sífilis gestacional en el último trimestre sobre la incidencia de sífilis congénita: revisión sistemática y metanálisis (2025) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The strategy of early diagnosis with rapid tests and immediate treatment (on the same day) with at least one dose of benzathine penicillin leads to a reduction of about 98% in the incidence of CS (relative risk (RR), 0.02; 95% confidence interval (CI: 0.00-0.18)”
From Efectividad del tratamiento de la sífilis gestacional en el último trimestre sobre la incidencia de sífilis congénita: revisión sistemática y metanálisis (2025) · cites this paper as [5]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Sexually Transmitted Infections Treatment Guidelines, 2021 > Syphilis > Congenital Syphilis
“a serum quantitative nontreponemal serologic titer that is fourfold§ (or greater) higher than the mother’s titer at delivery (e.g., maternal titer = 1:2, neonatal titer ≥1:8 or maternal titer = 1:8, neonatal titer ≥1:32)¶;”
§ Sexually Transmitted Infections Treatment Guidelines, 2021 > Syphilis > Congenital Syphilis
“a serum quantitative nontreponemal serologic titer equal to or less than fourfold of the maternal titer at delivery (e.g., maternal titer = 1:8, neonatal titer ≤1:16)”
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096
Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K., Hwang, J. P., Jonas, M. M., Brown, R. S., Bzowej, N. H., & Wong, J. B. (2018) · Hepatology · doi:10.1002/hep.29800 · Cited by 4,306
Nugent, R. P., Krohn, M. A., & Hillier, S. L. (1991) · Journal of Clinical Microbiology · doi:10.1128/jcm.29.2.297-301.1991 · Cited by 3,331
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten, J. M., Donnell, D., Ndase, P., Mugo, N. R., Campbell, J. D., Wangisi, J., Tappero, J. W., Bukusi, E. A., Cohen, C. R., Katabira, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108524 · Cited by 3,256
Classification of papillomaviruses
de Villiers, E.-M., Fauquet, C., Broker, T. R., Bernard, H.-U., & zur Hausen, H. (2004) · Virology · doi:10.1016/j.virol.2004.03.033 · Cited by 3,193
Coleman, E., Bockting, W., Botzer, M., Cohen-Kettenis, P., DeCuypere, G., Feldman, J., Fraser, L., Green, J., Knudson, G., Meyer, W. J., et al. (2012) · International Journal of Transgenderism · doi:10.1080/15532739.2011.700873 · Cited by 3,143
(2006) · PsycEXTRA Dataset · doi:10.1037/e545592006-001 · Cited by 2,958
Sexually transmitted diseases treatment guidelines (2015)
Workowski, K., & BOLAN, G. A. (2015) · Reproductive Endocrinology · doi:10.18370/2309-4117.2015.24.51-56 · Cited by 2,698
Self-citationAuvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020298 · Cited by 2,451
Research works printed but not linked: 12
- Golden MR, Kerani RP, Stenger M, Effect of expedited partner therapy (EPT) on chlamydial prevalence: the Washington State Community-Level Trial. Presented at the STD Prevention Conference, Minneapolis, MN; March 12–15, 2012.
- Benton S, Smith J, Wang F, Heitgerd J, Belcher L, Patel H. HIV testing, diagnosis, and linkage to care among persons tested in select CDC-funded health care and non-health care settings, 2012–2017. Presented at the National HIV Prevention Conference, Atlanta, GA: March 18–21, 2019.
- Briggs GC. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 11th ed. Philadelphia, PA: Wolters Kluwer; 2017.
- Blanco JL, Fuertes I, Bosch J, Effective treatment of lymphogranuloma venereum (LGV) with 1g azithormycin administered weekly for 3 weeks in HIV-infected population. Presented at the Conference on Retroviruses and Opportunist Infections, Seattle, WA; February 23–26, 2015.
- Rolfs, 1997, A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection., N Engl J Med, 337, 307, 10.1056/NEJM199707313370504 · DOI · Paper page
- Ahmed, 2012, Clinical outcome in the use of cephalosporins in pediatric patients with a history of penicillin allergy., Int Arch Allergy Immunol, 158, 405, 10.1159/000333553 · DOI · Paper page
- Park, 2011, Screening for syphilis with the treponemal immunoassay: analysis of discordant serology results and implications for clinical management., J Infect Dis, 204, 1297, 10.1093/infdis/jir524 · DOI · Paper page
- Muzny, 2014, Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic., Clin Infect Dis, 59, 834, 10.1093/cid/ciu446 · DOI · Paper page
- Sobel, 2001, Tinidazole therapy for metronidazole-resistant vaginal trichomoniasis., Clin Infect Dis, 33, 1341, 10.1086/323034 · DOI · Paper page
- Perkins, 2020, 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors., J Low Genit Tract Dis, 24, 102, 10.1097/LGT.0000000000000525 · DOI · Paper page
- Al Jaff, 2018, Comparison of the effectiveness of sulphur ointment, permethrin and oral ivermectin in treatment of scabies., Res J Pharm Biol Chem Sci, 9, 670
- Chiu S, Argaez C. Ivermectin for parasitic skin infections of scabies: a review of comparative clinical effectiveness, cost-effectiveness, and guidelines. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2019. https://www.ncbi.nlm.nih.gov/books/NBK545083/
Cited by
Standards of Care for the Health of Transgender and Gender Diverse People, Version 8
Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L. C., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., et al. (2022) · International Journal of Transgender Health · doi:10.1080/26895269.2022.2100644 · Cited by 2,698
Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections
Luetkemeyer, A. F., Donnell, D., Dombrowski, J. C., Cohen, S., Grabow, C., Brown, C. E., Malinski, C., Perkins, R., Nasser, M., Lopez, C., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2211934 · Cited by 468
Towards a deeper understanding of the vaginal microbiota
France, M., Alizadeh, M., Brown, S., Ma, B., & Ravel, J. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01083-2 · Cited by 382
Miller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gonzalez, M. D., Harrington, A., Jerris, R. C., Kehl, S. C., Leal, S. M., et al. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae104 · Cited by 376
Diagnosis and Treatment of Sexually Transmitted Infections: A Review
Tuddenham, S., Hamill, M. M., & Ghanem, K. G. (2022) · JAMA · doi:10.1001/jama.2021.23487 · Cited by 302
Metadata
- Authors
- Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A.
- Affiliations
- Emory University (US)
- National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention (US)
- Brown University (US)
- University of Washington (US)
- University of Alabama at Birmingham (US)
- Johns Hopkins University (US)
- Washington University in St. Louis (US)
- Corresponding author
- Workowski, Kimberly A.
- ORCID
- Venue
- MMWR. Recommendations and Reports
- Published
- 2021-07-23
- Volume
- 70
- Issue
- 4
- Pages
- 1-187
- ISSN
- 1057-5987 (ISSN-L)
- 1545-8601
- PMC
- PMC8344968
- OpenAlex
- W3185444663
- Semantic Scholar
- eb300ecb7d38078ce65557d8188da1edbd3174fc
- Cited by
- 3,018
- References
- 1,505
- Citations by year
- 2026: 740 · 2025: 655 · 2024: 606 · 2023: 558 · 2022: 385 · 2021: 64
- FWCI
- 256.76
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- public-domain
- Locations
- MMWR Recommendations and Reports (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (R25MH083620)
- Topics
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Health Sciences › Medicine › Epidemiology › Cervical Cancer and HPV Research
- Keywords
- sexually transmitted infections, STI treatment, gonorrhea, Chlamydia trachomatis, Trichomonas vaginalis, pelvic inflammatory disease, bacterial vaginosis, Mycoplasma genitalium, HPV vaccine, HCV screening, HIV prevention
- MeSH terms
- Centers for Disease Control and Prevention, U.S., Humans, Sexually Transmitted Diseases, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sexually Transmitted Infections Treatment Guidelines, 2021. https://app.cochat.ai/papers/10.15585/mmwr.rr7004a1
- The paper
- Workowski, K. A., Bachmann, L. H., Chan, P. A., Johnston, C. M., Muzny, C. A., Park, I., Reno, H., Zenilman, J. M., & Bolan, G. A. (2021). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and Reports. https://doi.org/10.15585/mmwr.rr7004a1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
